India Exchange Filings

Board Meeting and Q2 FY27 Results Highlights

Gufic Biosciences Ltd reports Q2 FY27 consolidated revenue of ₹288.27 crore and net profit of ₹23.47 crore

  • Revenue rose 10.5% sequentially and 21.6% year on year; net profit increased 5.2% sequentially and 39.5% year on year.
  • Board approved Dr. Reeta Shah’s appointment as Additional Non-Executive Independent Director for five years from December 1, 2026, subject to shareholder approval.
  • Auditors’ limited reviews noted no matter indicating a material misstatement; no exceptional items were reported.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.